Business
Resverlogix's Lead Drug Featured in Key Scientific Publication
RVX-208 is the only Apo-Al/HDL drug to be highlighted TSX Exchange Symbol: RVX CALGARY, July 18 /...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nRVX-208 is the only Apo-Al/HDL drug to be highlighted\n\n\nTSX Exchange Symbol: RVX\n\n\nCALGARY, July 18 /CNW/ - Resverlogix Corp. ("Resverlogix" or the\n"Company") (TSX:RVX) is pleased to announce that Resverlogix's lead drug is\nfeatured prominently in an article titled "Emerging Antidyslipidemic Drugs",\nwhich appears in the current edition of Expert Opinion of Emerging Drugs, a\nwell respected scientific journal for the pharmaceutical industry. The article\nwritten by Drs.' Pollex, Joy and Hegele provides an overview of current and\nupcoming dyslipidemic drugs.\n\n\n"To be the only ApoA-l/HDL drug highlighted in an esteemed journal such\nas Expert Opinion of Emerging Drugs speaks volumes as to the excitement felt\nin the scientific community for our lead drug RVX-208," stated \nDonald McCaffrey, President and CEO of Resverlogix. "The data provided to the\nauthors was our preclinical data. The Phase 1a data which we recently\nannounced illustrated very similar trending as the African Green Monkey data\nof increased ApoA-I production and HDL functionality, thus our enthusiasm\ncontinues to build as we head into our Phase 1b/2a trial later this year."\n\n\nRVX-208 is a first-in-class small molecule that facilitates endogenous\nApoA-I production. It is positioned as one of the most promising emerging\ndrugs in the treatment of atherosclerosis, the largest medical market in the\nworld with a critical unmet need. To the Company's knowledge RVX-208 is the\nonly novel small molecule that is specifically designed to increase ApoA-I\nproduction. Consequently this raises functional HDL levels which in turn\nenhance reverse cholesterol transport, atherosclerosis regression and\nultimately reduction of major adverse cardiovascular events (MACE).\n\n\nAbout Resverlogix Corp.\n\n\nResverlogix Corp. is a leading biotechnology company engaged in the\ndevelopment of novel therapies for important global medical markets with\nsignificant unmet needs. The NexVas(TM) program is the Company's primary focus\nwhich is to develop novel small molecules that enhance ApoA-I. These vital\ntherapies address the grievous burden of atherosclerosis and other important\ndiseases such as acute coronary syndrome, diabetes, Alzheimer's disease and\nother vascular disorders. The Company's secondary focus ...